Arcadia Biosciences, Inc. Forecast, price target & analysts
Arcadia Biosciences, Inc. Target price 2026 - Analyst rating & recommendation
Arcadia Biosciences, Inc. Classifications & Recommendation
Arcadia Biosciences, Inc. Price Target
| Target Price | $12.24 |
| Price | $0.31 |
| Potential |
3,879.19%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Arcadia Biosciences, Inc. 2027 .
The average Arcadia Biosciences, Inc. target price is $12.24.
This is
3,879.19%
register free of charge
$12.60
3,996.23%
register free of charge
$12.12
3,840.18%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Arcadia Biosciences, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arcadia Biosciences, Inc. stock has an average upside potential 2027 of
3,879.19%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 4.86 | 7.85 |
| 3.76% | 61.60% | |
| EBITDA Margin | -66.26% | -48.68% |
| 54.48% | 26.53% | |
| Net Margin | -48.15% | -68.51% |
| 65.46% | 42.29% |
3 Analysts have issued a sales forecast Arcadia Biosciences, Inc. 2026 . The average Arcadia Biosciences, Inc. sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2025 | $4.9m | 3.76% |
|---|---|---|
| 2026 |
$7.9m
61.60%
unlock
|
|
3 Analysts have issued an Arcadia Biosciences, Inc. EBITDA forecast 2026. The average Arcadia Biosciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-3.2m | 56.19% |
|---|---|---|
| 2026 |
$-3.8m
18.73%
unlock
|
|
EBITDA Margin
| 2025 | -66.26% | 54.48% |
|---|---|---|
| 2026 |
-48.68%
26.53%
unlock
|
|
3 Arcadia Biosciences, Inc. Analysts have issued a net profit forecast 2026. The average Arcadia Biosciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2025 | $-2.3m | 66.76% |
|---|---|---|
| 2026 |
$-5.4m
129.91%
unlock
|
|
Net Margin
| 2025 | -48.15% | 65.46% |
|---|---|---|
| 2026 |
-68.51%
42.29%
unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.71 | -2.47 |
| 66.86% | 44.44% | |
| P/E | negative | |
| EV/Sales | negative |
3 Analysts have issued a Arcadia Biosciences, Inc. forecast for earnings per share. The average Arcadia Biosciences, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2025 | $-1.71 | 66.86% |
|---|---|---|
| 2026 |
$-2.47
44.44%
unlock
|
|
P/E ratio
| Current | -0.08 | 87.38% |
|---|---|---|
| 2026 |
-0.12
44.75%
unlock
|
|
Based on analysts' sales estimates for 2026, the Arcadia Biosciences, Inc. stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | -0.72 | 900.00% |
|---|---|---|
| 2026 |
-0.44
39.17%
unlock
|
|
P/S ratio
| Current | 0.16 | 82.95% |
|---|---|---|
| 2026 |
0.09
39.62%
unlock
|
|
Arcadia Biosciences, Inc....
Current Arcadia Biosciences, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 21 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 21 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
